Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Reproductive Health Services

 
In compliance with the decisions of the International Conference on Population and Development in 1994 on behalf of the Government of Lebanon, the “Reproductive Health Program” was established at the Ministry of Public Health and supported by the United Nations Population Fund (UNFPA) under the umbrella of primary health care with a clear strategy between 1998 and 2001. The program is still ongoing through its integration within the primary health care department.

The Ministry of Public Health / Primary Health Care Department in collaboration with UNFPA provides various services regarding reproductive health and family planning in agreement with the joint annual work plan signed between the two parties.

The health services can be summarized in the following categories:
  • Family planning
  • Safe motherhood and Newborn Health
  • Diagnostic & Preventive Check-ups
  • Screening for Reproductive system diseases and reproductive tract cancers

I. Reproductive Health Services
The primary health care department provides preventive services in order to improve the health of the family (women, children, youth and men) through:
  • Providing reproductive health medications and supplies through PHC centers, including 57 health centers / clinics outside the primary health care network, and providing reproductive health services to the displaced in order to improve women's health and prevent unwanted pregnancies.
  • Delivering reproductive health information to beneficiaries through awareness and education programs which are provided by the primary health care centers within and outside the centers.
  • Providing equipment that enables early detection of reproductive system diseases (early detection of breast cancer, cervical cancer).
  • Encouraging pregnant women to receive a minimum of 4 visits during pregnancy and one postnatal visit.
  • Developing the capacity of service providers in primary health care centers based on the clinical protocols for reproductive health.
  • Preparing governmental hospitals to receive emergency obstetric cases.
  •  Equipping governmental hospitals to receive high-risk pregnancies.
  •  Capacity building of service providers to deal with survivors of sexual violence and refer them to relevant associations.
  • Capacity building of service providers of provision of equipment for primary health care centers and hospitals to address cases of rape and refer survivors to the relevant associations.
 

II. Antenatal and Postnatal Care Services:
The primary health care department offers as well antenatal and postnatal care services for pregnant Lebanese and non-Lebanese women across Lebanon as part of the reproductive health services. These services were supported by the formulation of the ‘’Service Delivery Guidelines’’, which were followed by consecutive training for primary health care (PHC) centers’ staff across Lebanon upon implementation.

The antenatal and postnatal care services offered by the PHC centers consist of the following:
All pregnant women visiting the centers should receive:
  1.  Minimum of 4 antenatal care services
  2.  2 Echography during pregnancy
  3.  1 postnatal visit
  4.  Coverage of vaccination for newborn of followed up mothers (according to the National Vaccination Calendar)
  5.  Provision of Reproductive Health drugs and supplies to all PHC centers, in addition to 64 Reproductive Health dispensaries supported by International NGOs to serve the displaced Syrians.
 

III. Service Delivery Guidelines for Reporoductive Health Care:
MoPH with the support of UNFPA and in collaboration with the Lebanese Society of Obstetrics & Gynecology (LSOG) launched " The Revised Version of the Service Delivery Guidelines for Reproductive Health" in June 2015, which aimed at improving the knowledge and skills of service providers, in order to ensure the provision of reproductive health services that meet women's, men's and youth's needs in Lebanon.

Accordingly, the first phase of training took place from July to September, with 275 physicians and health care workers, including: 160 paramedical specialties, 88 medical and 27 humanitarian actors.

The training aims to improve the knowledge, skills and confidence of health workers to ensure that reproductive health needs of women, men adults and youth are met in normal setting and in the case of crises.
 
IV. Project Reports:
    1
ATC Name B/G Ingredients Dosage Form Price
S01ED51 XALACOM B Timolol (maleate) - 6.8mg/ml, Latanoprost - 50?g/ml Drops solution 510,660 L.L
S01EE01 XALAPROST G Latanoprost - 0.005% w/v 0.005% w/v Drops solution 421,967 L.L
S01EE01 XALATAN B Latanoprost - 50mcg/ml 50mcg/ml Drops solution 704,173 L.L
N05AX12 XALIPRO G Aripiprazole - 10mg 10mg Tablet 2,123,271 L.L
N05AX12 XALIPRO G Aripiprazole - 15mg 15mg Tablet 2,418,917 L.L
N05AX12 XALIPRO G Aripiprazole - 5mg 5mg Tablet 1,746,995 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
N05BA12 XANAX B Alprazolam - 0.5mg 0.5mg Tablet 477,064 L.L
B01AF01 XARELTO B Rivaroxaban - 2.5mg 2.5mg Tablet, film coated 4,045,168 L.L
B01AF01 XARELTO B Rivaroxaban - 15mg 15mg Tablet, film coated 4,440,862 L.L
B01AF01 XARELTO B Rivaroxaban - 20mg 20mg Tablet, film coated 4,440,862 L.L
B01AF01 XARELTO B Rivaroxaban - 10mg 10mg Tablet, film coated 1,588,892 L.L
G04CA01 XATRAL XL B Alfuzosin HCl - 10mg 10mg Tablet, prolonged release 1,061,636 L.L
B01AF01 XAVIRAN G Rivaroxaban - 15mg 15mg Tablet, film coated 952,208 L.L
B01AF01 XAVIRAN G Rivaroxaban - 20mg 20mg Tablet, film coated 952,208 L.L
B01AF01 XAVIRAN G Rivaroxaban - 10mg 10mg Tablet, film coated 606,649 L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet L.L
L04AA29 XELJANZ B Tofacitinib - 5mg 5mg Tablet 80,685,473 L.L
L04AA29 XELJANZ XR B Tofacitinib - 11mg 11mg Tablet, extended release 78,687,316 L.L
L01BC06 XELODA B Capecitabine - 500mg 500mg Tablet, film coated 17,946,398 L.L
D07AC13 XEMADERM G Mometasone furoate - 0.1% 0.1% Cream 335,961 L.L
A08AB01 XENICAL B Orlistat - 120mg 120mg Capsule 4,036,903 L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 100 units LD50 100 units LD50 Injectable powder for solution 20,517,541 L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 50 units LD50 50 units LD50 Injectable powder for solution 11,920,109 L.L
J01DD15 XEVANEER G Cefdinir - 300mg 300mg Capsule 1,350,562 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 1,308,903 L.L
J01DD15 XEVANEER G Cefdinir - 125mg/5ml 125mg/5ml Powder for suspension 686,704 L.L
M05BX04 XGEVA BioTech Denosumab - 120mg 120mg Injectable solution 33,545,669 L.L
    1
Sitemap
© Copyrights reserved to Ministry of Public Health 2026